Loading…
Danish medical device maker of ostomy, continence, urology and wound/skin care products.
Danish medical device maker of ostomy, continence, urology and wound/skin care products.
Patients need ostomy and continence supplies every day, often for life, so revenue repeats once a patient is set up on a product. Sales go through hospital tenders, home-delivery services and distributors, usually reimbursed by health systems, and hospital nurses influence the first choice of product.
Moat: wide (brand, switching costs, distribution). Patients build habitual loyalty to specific ostomy/continence product lines, raising switching costs.
Headquarters: Humlebaek, Denmark · Founded: 1957 · Employees: 17,524
Size Coloplast A/S (COLO-B.CO) is a Denmark Health Care company (Medical Specialties) with a market value of $17.7B, the 10th largest of 59 Denmark companies the cockpit tracks. Shares closed at DKK 508.20 on 6 Nov 2026.
Performance Over six months the shares gained 26.2%, against +28.7% for the median peer and +8.8% for the Denmark market (cap-weighted) — 10th lowest of 21 in its peer set.
Growth Revenue grew 3.8% over the last twelve months (peer median +6.2%); the operating margin is 25.4% (peer median 16.6%).
Valuation It trades at 19.9× forward earnings against a peer median of 25.6× (7th cheapest of 20).
Price implies For today's price to make sense, revenue must grow about -2% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is -10 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 11.2 points above its cost of capital (5.1% WACC).
Credit Coloplast A/S has 2 bonds outstanding ($1.73B), rated BBB+ by the agencies and trading like BBB- at a weighted spread of 130 bp.
Next results Next results expected around 5 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|---|
| Revenue | DKK 28.9B | DKK 28.9B | DKK 27.9B | DKK 27.0B | DKK 24.5B |
| Revenue growth | — | +4% | +3% | +10% | — |
| Gross profit | DKK 17.6B | DKK 18.4B | DKK 18.1B | DKK 17.5B | DKK 15.7B |
| EBITDA | DKK 11.8B | DKK 8.79B | DKK 8.93B | DKK 8.70B | DKK 7.86B |
| Net income | DKK 3.07B | DKK 3.07B | DKK 3.64B | DKK 5.05B | DKK 4.78B |
| Free cash flow | DKK 6.62B | DKK 6.62B | DKK 5.34B | DKK 1.60B | DKK 3.21B |
| Capital expenditure | DKK 1.57B | DKK 1.57B | DKK 1.43B | DKK 1.35B | DKK 1.24B |
| Total debt | DKK 21.5B | DKK 21.5B | DKK 22.6B | DKK 22.6B | DKK 19.6B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Coloplast A/S COLO-B.CO | $17.7B | +26% | +4% | 25% | 19.9× | -1.8% |
| ConvaTec CTEC.L | $6.44B | +22% | +2% | 16% | 16.7× | 15.6% |
| Medtronic MDT | $130B | +35% | +10% | 20% | 16.9× | 8.6% |
| Smith & Nephew SN..L | $13.1B | +5% | +2% | 17% | 14.4× | 11.1% |
| Solventum SOLV | $15.4B | +23% | -1% | 8% | 12.2× | n/a |
| Teleflex TFX | $6.39B | +13% | -14% | 11% | 16.8× | 17.8% |
| Becton Dickinson BDX | $57.7B | +43% | -3% | 15% | 16.0× | 9.6% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | COLO-B.CO | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +19.7% | +13.8% | 2nd highest of 21 |
| 6-month return | +26.2% | +28.7% | 10th lowest of 21 |
| Distance from 52-week high | -19.5% | -10.8% | 6th lowest of 21 |
| Revenue growth (TTM) | +3.8% | +6.2% | 5th lowest of 21 |
| Operating margin | 25.4% | 16.6% | highest of 21 |
| Forward P/E | 19.9× | 25.6× | 7th cheapest of 20 |
| Growth the price implies (Req g, 7 yrs) | -1.8% | 11.4% | least demanding of 18 |
| Growth delivered (Del g) | +8.3% | +9.2% | 8th lowest of 18 |
| Hurdle (Req g minus delivered) | -10.1 pp | +2.4 pp | least demanding of 18 |
| ROIC minus cost of capital | +11.2 pp | +1.5 pp | 2nd highest of 21 |
| EV / EBITDA | 11.8× | 15.7× | 5th cheapest of 17 |
| Net debt / EBITDA | 1.8× | 1.4× | 9th least indebted of 17 |
| Bond spread | 130 bp | 95 bp | widest of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Coloplast A/S COLO-B.CO | Denmark | $17.7B | +26% | +4% | 25% | 19.9× | -1.8% | +8.3% |
| Revvity RVTY | United States | $17.3B | +54% | +5% | 15% | 26.7× | 27.3% | -5.5% |
| Sartorius SRT.DE | Germany | $20.0B | +34% | +4% | 18% | 42.6× | 24.9% | +8.7% |
| Zimmer Biomet ZBH | United States | $20.1B | +29% | +7% | 16% | 12.0× | -1.4% | +3.2% |
| Guardant Health GH | United States | $20.2B | +58% | +43% | -40% | n/a | n/a | n/a |
| Sonova SOON.SW | Switzerland | $20.3B | +62% | -7% | 21% | 25.6× | 7.1% | +6.7% |
| Straumann STMN.SW | Switzerland | $20.4B | +25% | +2% | 21% | 31.9× | 15.2% | +12.8% |
| Shanghai United Imaging Healthcare 688271.SS | China | $14.8B | +9% | +27% | 9% | 46.9× | n/a | n/a |
| Lenskart Solutions LENSKART.NS | India | $13.4B | +49% | +35% | 10% | 137.4× | 52.8% | +33.5% |
| Baxter International BAX | United States | $13.3B | +43% | +5% | 6% | 12.6× | 12.7% | -0.7% |
| Terumo 4543.T | Japan | $23.4B | +25% | +14% | 17% | 24.6× | 8.7% | +13.0% |
| Glaukos GKOS | United States | $13.3B | +68% | +47% | -9% | 155.4× | n/a | n/a |
| Smith & Nephew SN..L | United Kingdom | $13.1B | +5% | +2% | 17% | 14.4× | 11.1% | +5.6% |
| Steris STE | United States | $24.6B | +22% | +8% | 20% | 21.4× | 13.7% | +13.8% |
| Sartorius Stedim Biotech DIM.PA | France | $24.7B | +38% | +4% | 19% | 45.5× | 33.1% | +9.2% |
| Penumbra PEN | United States | $12.6B | -1% | +17% | 12% | 54.9× | 30.1% | +20.2% |
| bioMerieux BIM.PA | France | $12.4B | +29% | -3% | 15% | 20.9× | 8.9% | +5.5% |
| Olympus 7733.T | Japan | $12.2B | +13% | +8% | 16% | 18.0× | -1.5% | +6.7% |
| Cooper Companies (The) COO | United States | $11.9B | +4% | +5% | 19% | 13.8× | 9.4% | +11.0% |
| Align Technology ALGN | United States | $11.8B | -2% | +4% | 19% | 13.9× | 11.4% | +10.3% |
| Demant A/S DEMANT.CO | Denmark | $11.6B | +62% | +10% | 18% | 25.7× | 6.8% | +9.8% |
Coloplast A/S has 2 bonds outstanding with $1.73B face value. The agencies rate it BBB+; its bonds trade like BBB-. Weighted yield 4.27%, a spread of 130 bp over government bonds.